http://www.fpnotebook.com/
Osteoporosis ManagementAka: Osteoporosis Prevention
- See also
- Osteoporosis
- Osteoporosis Evaluation
- Osteoporosis Secondary Causes
- Medication Causes of Osteoporosis
- Indications: Treatment with Osteoporosis agents
- Hip Fracture or vertebral Fracture history or
- Other Fracture site AND Osteopenia at femoral neck, hip or spine (T-Score -1.0 to -2.5) or
- Osteoporosis based on femoral neck, hip or spine BMD (T-Score <-2.5)
- Evaluate for Osteoporosis Secondary Causes prior to treatment
- Osteopenia AND high Fracture risk secondary cause (e.g. prolonged glucocorticoid use)
- Osteopenia (T score -1.0 to -2.5) AND abnormal FRAX Score
- See Frax Calculator
- http://www.shef.ac.uk/FRAX/
- Requires hip Bone Mineral Density
- FRAX score (10 year Fracture probability) of Hip Fracture >3% or
- FRAX score for any Osteoporosis related Fracture >20%
- Management: General measures and prevention for all patients
- Dietary Supplementation
- Calcium Supplementation 1200 to 1500 mg per day
- Does not increase bone density (but slows loss)
- Overdosage above 1500 mg daily weakens bone
- Vitamin D Supplementation 800 to 1000 IU orally per day
- Increases bone density 1% per year
- Weight bearing Exercise
- See Exercise in Osteoporosis
- Smoking Cessation
- Limit Alcohol to moderate use (<3 drinks per day)
- Limit Proton Pump Inhibitor use ( Associated with higher risk of Hip Fractures)
- Yang (2006) JAMA 296:2947
- Fall prevention and Hip Fracture prevention
- See Fall Prevention in the Elderly
- See Hip Protectors (underwear with trochanter pads)
- Management: Osteoporosis Treatments considered effective
- General
- See Indications as above
- See General measures for all patients as above
- Bisphosphonates
- Increases bone density 5-6% per year
- Alendronate
- Risedronate
- Estrogen Replacement Therapy (ERT or HRT)
- Standard Dosing
- Minimum preventive plasma estradiol level: 60 pg/ml
- Maximal effect requires Premarin 0.625
- Increases bone density 3-4% per year
- Alternative Estrogen dosing
- Some effect seen at 0.3 mg or Transdermal Estrogen
- 17-beta-estradiol 0.25 mg increases BMD
- Prestwood (2003) JAMA 290:1042
- Fracture protection lost 5 years after stopping ERT
- Yates (2004) Obstet Gynecol 103:440
- Selective Estrogen Receptor Modulator (e.g. Raloxifene)
- Similar benefit to Estrogen Replacement
- Indicated if unable to take Estrogen Replacement
- Calcitonin
- Increases bone density 1-2% per year
- Teriparatide (Forteo)
- Recombinant Parathyroid Hormone
- Limits: Do not use with bisphosphonate and do not use longer than 2 years
- Efficacy: Reduced risk for osteoporotic Fractures
- Neer (2001) N Engl J Med 344:1434
- Management: Osteoporosis treatments of questionable efficacy
- Fluoride Supplementation
- Increases bone density 10% per year
- Unclear whether bone strength is increased
- Management: Agents under investigation for possible benefit in Osteoporosis
- HMG-CoA Reductase Inhibitor (Statin drugs)
- Thiazide Diuretics (e.g. Hydrochlorothiazide)
- Decreases urinary calcium loss
- Reduction in Hip Fracture if used >10 years
- Consider in hypertensive patients
- LaCroix (2000) Ann Intern Med 133:516
- Dietary magnesium 600 mg/day or more
- Dietary Soy Protein 40 grams/day or more
- Scheiber (1999) {a 8169} 6:233
- References
- Andrews (1998) Postgrad Med 104(4):89
- Campion (2003) Am Fam Physician 67(7):1521
- Lindsay (1984) Obstet Gynecol 63:759
- South-Paul (2001) Am Fam Physician 63(6):1121
- Taxel (1998) {a 6611} 53(8):22
Navigation Tree